Literature DB >> 10433799

Contribution of the innate immune system to autoimmune diabetes: a role for the CR1/CR2 complement receptors.

H Noorchashm1, D J Moore, Y K Lieu, N Noorchashm, A Schlachterman, H K Song, C F Barker, A Naji.   

Abstract

B lymphocytes are required for diabetogenesis in nonobese diabetic (NOD) mice. The complement component of the innate immune system regulates B cell activation and tolerance through complement receptors CR1/CR2. Thus, it is important to assess the contribution of complement receptors to autoimmune diabetes in NOD mice. Examination of the lymphoid compartments of NOD mice revealed striking expansion of a splenic B cell subset with high cell surface expression of CR1/CR2. This subset of B cells exhibited an enhanced C3 binding ability. Importantly, long-term in vivo blockade of C3 binding to CR1/CR2 prevented the emergence of the CR1/CR2(hi) B cells and afforded resistance to autoimmune diabetes in NOD mice. These findings implicate complement as an important regulatory element in controlling the T cell-mediated attack on islet beta cells of NOD mice. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433799     DOI: 10.1006/cimm.1999.1522

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  Regulation of B lymphocyte responses to Toll-like receptor ligand binding during diabetes prevention in non-obese diabetic (NOD) mice.

Authors:  Christopher S Wilson; Sydney K Elizer; Andrew F Marshall; Blair T Stocks; Daniel J Moore
Journal:  J Diabetes       Date:  2015-03-03       Impact factor: 4.006

2.  Healthy Donor Polyclonal IgMs Diminish B-Lymphocyte Autoreactivity, Enhance Regulatory T-Cell Generation, and Reverse Type 1 Diabetes in NOD Mice.

Authors:  Christopher S Wilson; Preeti Chhabra; Andrew F Marshall; Caleigh V Morr; Blair T Stocks; Emilee M Hoopes; Rachel H Bonami; Greg Poffenberger; Kenneth L Brayman; Daniel J Moore
Journal:  Diabetes       Date:  2018-08-21       Impact factor: 9.461

3.  Genes within the Idd5 and Idd9/11 diabetes susceptibility loci affect the pathogenic activity of B cells in nonobese diabetic mice.

Authors:  Pablo A Silveira; Harold D Chapman; Jessica Stolp; Ellis Johnson; S Lewis Cox; Kara Hunter; Linda S Wicker; David V Serreze
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

4.  In vivo islet protection by a nuclear import inhibitor in a mouse model of type 1 diabetes.

Authors:  Daniel J Moore; Jozef Zienkiewicz; Peggy L Kendall; Danya Liu; Xueyan Liu; Ruth Ann Veach; Robert D Collins; Jacek Hawiger
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

5.  Immune cell-derived c3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin.

Authors:  Marvin Lin; Na Yin; Barbara Murphy; M Edward Medof; Stephan Segerer; Peter S Heeger; Bernd Schröppel
Journal:  Diabetes       Date:  2010-06-28       Impact factor: 9.461

Review 6.  Mechanisms of lymphatic system-specific viral replication and its potential role in autoimmune disease.

Authors:  S-K Friedrich; P A Lang; J Friebus-Kardash; V Duhan; J Bezgovsek; K S Lang
Journal:  Clin Exp Immunol       Date:  2019-01       Impact factor: 4.330

7.  In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice.

Authors:  Ghazal Zekavat; Susan Y Rostami; Armen Badkerhanian; Ronald F Parsons; Brigitte Koeberlein; Ming Yu; Christopher D Ward; Thi-Sau Migone; Liping Yu; George S Eisenbarth; Michael P Cancro; Ali Naji; Hooman Noorchashm
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Follicular B cells in thyroids of mice with spontaneous autoimmune thyroiditis contribute to disease pathogenesis and are targets of anti-CD20 antibody therapy.

Authors:  So-Hee Hong; Helen Braley-Mullen
Journal:  J Immunol       Date:  2013-12-27       Impact factor: 5.422

9.  Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.

Authors:  Kamal D Puri; Michael R Gold
Journal:  Front Immunol       Date:  2012-08-23       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.